In the past week, RGLS stock has gone up by 0.74%, with a monthly gain of 4.32% and a quarterly surge of 486.43%. The volatility ratio for the week is 0.68%, and the volatility levels for the last 30 days are 0.82% for Regulus Therapeutics Inc. The simple moving average for the past 20 days is 1.87% for RGLS’s stock, with a 208.11% simple moving average for the past 200 days.
Is It Worth Investing in Regulus Therapeutics Inc (NASDAQ: RGLS) Right Now?
The 36-month beta value for RGLS is at 0.37. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
The public float for RGLS is 57.32M, and currently, shorts hold a 3.64% of that float. The average trading volume for RGLS on June 20, 2025 was 2.12M shares.
RGLS) stock’s latest price update
The stock price of Regulus Therapeutics Inc (NASDAQ: RGLS) has jumped by 0.12 compared to previous close of 8.20. Despite this, the company has seen a gain of 0.74% in its stock price over the last five trading days. globenewswire.com reported 2025-05-27 that Basel, May 27, 2025 – Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. Such offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 27, 2025, and the related Letter of Transmittal (together, the “Offer”) and pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of April 29, 2025 (the “Merger Agreement”), among Novartis, Purchaser and Regulus.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with Wells Fargo repeating the rating for RGLS by listing it as a “Overweight.” The predicted price for RGLS in the upcoming period, according to Wells Fargo is $6 based on the research report published on March 27, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $7. The rating they have provided for RGLS stocks is “Outperform” according to the report published on August 02nd, 2024.
Leerink Partners gave a rating of “Outperform” to RGLS, setting the target price at $6 in the report published on March 18th of the previous year.
RGLS Trading at 31.08% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGLS starting from Klassen Preston, who purchase 12,000 shares at the price of $7.99 back on Jun 03 ’25. After this action, Klassen Preston now owns 48,055 shares of Regulus Therapeutics Inc, valued at $95,852 using the latest closing price.
Hagan Joseph P, the Chief Executive Officer of Regulus Therapeutics Inc, purchase 50,000 shares at $1.09 during a trade that took place back on Jan 30 ’25, which means that Hagan Joseph P is holding 260,808 shares at $54,260 based on the most recent closing price.
Stock Fundamentals for RGLS
The total capital return value is set at -0.73. Equity return is now at value -53.82, with -50.30 for asset returns.
Based on Regulus Therapeutics Inc (RGLS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.08. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -877.19.
Currently, EBITDA for the company is -45.85 million with net debt to EBITDA at 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.52.
Conclusion
In conclusion, Regulus Therapeutics Inc (RGLS) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
